NOMAD POWER SOLUTIONS, INC.

Lixte Biotechnology Holdings, Inc. (trading on The Stock Market LLC) is a clinical-stage biopharmaceutical company focused on developing cancer therapies and proton therapy systems. The company operates through two primary business segments: its pharmaceutical division developing protein phosphatase inhibitors and its investment in proton therapy technology through its majority stake in Liora Technologies Europe Ltd.

The company's lead pharmaceutical candidate is LB-100, a small molecule inhibitor of protein phosphatase 2A designed to enhance the effectiveness of existing cancer treatments including chemotherapy, immunotherapy, and radiation. Preclinical studies have demonstrated that LB-100 potentiates DNA-damaging anti-cancer drugs and enhances immune checkpoint inhibition by increasing CD8+ T-cell infiltration and cytokine production. LB-100 holds FDA Investigational New Drug status in the United States and Investigational Medicinal Product Dossier approval in the European Union. The company is currently conducting multiple clinical trials evaluating LB-100 in combination with standard cancer therapies, including Phase 1b/2 trials in ovarian clear cell carcinoma combined with dostarlimab at MD Anderson Cancer Center and Northwestern University's Lurie Cancer Center, and a Phase 1b trial in microsatellite stable metastatic colon cancer combined with atezolizumab at the Netherlands Cancer Institute.

Through its majority ownership of Liora Technologies Europe Ltd., Lixte is developing the LiGHT System, a linear accelerator-based proton therapy platform designed to deliver ultra-high-dose-rate FLASH radiotherapy. The LiGHT System represents a disruptive technology alternative to traditional cyclotron-based proton therapy systems, offering reduced radiation shielding requirements, faster depth modulation, and lower installation costs. The system has demonstrated the ability to generate a 230 MeV proton beam and is currently a non-clinical prototype located at Daresbury Laboratory in the United Kingdom.

Lixte maintains an extensive patent portfolio covering LB-100 composition, formulations, and combination therapies with various cancer treatments. The company operates with minimal overhead, contracting research and development activities to external laboratories and manufacturers, and relies on periodic equity financing to fund operations and clinical development activities.